This is a working overview of 稳定性, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-16 and is reviewed periodically as new material appears.
Common analytical approaches include reversed-phase high-performance liquid chromatography for purity assessment and mass spectrometry for identity confirmation. Peptide mapping after enzymatic digestion can verify the expected sequence. Immunoassays may be used to measure the compound or its downstream markers, but they can cross-react with related peptides and require careful validation. Impurity profiles typically include truncated sequences, oxidized methionine residues, and residual solvents from synthesis. Each method reports a different property, so no single assay establishes overall quality.
Storage claims vary across suppliers, and published stability data for specific formulations are limited. Extrapolating from related peptides is common but not a substitute for direct measurement. For research use, documentation such as a certificate of analysis is often requested to confirm identity and purity. What constitutes an acceptable purity threshold depends on the intended application. Open questions remain about how temperature excursions during shipping affect long-term peptide integrity. Independent verification by an end user is not routinely reported.
Lyophilized tesamorelin is generally stored refrigerated at 2 to 8 degrees Celsius, protected from light and moisture. Peptides in this class are often kept frozen at minus 20 degrees Celsius for longer periods. Reconstituted solutions are typically used within a defined window because hydrolysis and oxidation proceed faster in liquid form. Container material and headspace also influence how long a preparation retains its expected profile. Specific stability figures depend on concentration and buffer composition.
研究用与临床用材料的标准并不相同。质量控制通常覆盖纯度、残留溶剂、反离子含量、微生物限度与内毒素水平，各项均有对应检测方法。随货文件应包含批号、检测项目、方法与结果，使数据可以追溯。核验时应关注纯度是否按主峰面积计算、杂质是否已定性、方法是否经过验证，这些信息决定结果能否被外部重复。
纯度与身份确认依赖色谱与质谱的组合。反相高效液相色谱在 214 nm 紫外检测下分离主峰与相关杂质，给出纯度百分比与保留时间；电喷雾或基质辅助激光解吸电离质谱提供分子量，用于确认 N 端修饰是否完整。序列层面可通过肽图或氨基酸分析验证。含量测定常用紫外吸收法或氮元素分析，不同方法之间需要做交叉校验。
冻干粉末一般在 -20°C 或更低温度、干燥避光条件下保存，可维持较长时间的稳定。复溶后稳定性明显下降，溶液中的肽链易发生水解、氧化与聚集，通常需冷藏并在短期内用完。反复冻融会加速聚集与降解，建议分装后单次使用。缓冲体系的 pH 与离子强度同样影响聚集速率，需要按具体实验条件验证。
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized powder | Requires reconstitution before use |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Storage, powder | 2 to 8 degrees Celsius | Protect from light and moisture |
| Storage, solution | Refrigerated, short term | Use promptly after reconstitution |
| Common assays | Reversed-phase HPLC and mass spectrometry | Purity and identity respectively |
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
Quantitation of the peptide relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection, typically at 214 nanometers, where the peptide bond absorbs. Identity is confirmed by mass spectrometry, most often electrospray ionization coupled to liquid chromatography, and by peptide mapping after enzymatic digestion. Because related impurities differ only slightly in sequence or modification, method development emphasizes resolution rather than speed. Purity is usually reported as a percentage of the main peak area, with individual impurities listed separately when they exceed a defined reporting threshold.
Research supply is often accompanied by a certificate of analysis listing chromatographic purity, mass confirmation, and storage conditions. Laboratories compare that document with an independent test when material is intended for bench work, since certificates describe a batch rather than an individual vial. Published studies usually state the source and purity of the peptide because small differences in purity can shift measured activity. Full analytical validation is rarely reported, which leaves batch-to-batch comparability an open question.
The peptide is supplied as a lyophilized powder in single-use vials and is normally kept refrigerated between two and eight degrees Celsius, protected from light. Once dissolved, the solution is handled carefully because peptide bonds and the acyl modification can degrade under warm or alkaline conditions. Vials are inspected for cracks, and the powder is checked for color and uniformity before handling. Temperature excursions during shipping are a frequent reason for quality questions.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from truncated or oxidized forms. Mass spectrometry confirms the expected molecular weight, and peptide mapping after enzymatic digestion verifies the amino acid sequence. Water content is measured because residual moisture affects stability, and tests for aggregates or particulates are standard for injectable peptides. Circular dichroism can indicate whether the molecule has adopted an unexpected secondary structure in solution.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
=== Human === The human FPR2 gene encodes the 351 amino acid receptor, FPR2, within an intronless open reading frame. It forms a cluster with FPR1 and FPR3 genes on chromosome 19q.13.3 in the order of FPR1, FPR2, and FPR3; this cluster also includes the genes for two other chemotactic factor receptors, the G protein-coupled C5a receptor (also termed CD88) and a second C5a receptor, GPR77 (i.e. C5a2 or C5L2), which has the structure of G protein receptors but apparently does not couple to G proteins and is of uncertain function. The FPR1, FPR2, and FPR3 paralogs, based on phylogenetic analysis, originated from a common ancestor with early duplication of FPR1 and FPR2/FPR3 splitting with FPR3 originating from the latest duplication event near the origin of primates.
== Relation to humans == Arapaima is exploited in many ways by local human populations. Its tongue is thought to have medicinal qualities in South America. It is dried and combined with guarana bark, which is grated and mixed into water. Doses are given to kill intestinal worms. The bony tongue is used to scrape cylinders of dried guarana, an ingredient in some beverages, and the bony scales are used as nail files. Arapaima produce boneless steaks and are considered a delicacy. In the Amazon region, locals often salt and dry the meat, rolling it into a cigar-style package that is then tied and can be stored without rotting, which is important in a region with little refrigeration. Arapaima are referred to as the "cod of the Amazon", and can be prepared in the same way as traditional salted cod. Designers have begun using the skin of the arapaima as leather to make jackets, shoes, and handbags, and to cover furniture. In July 2009, villagers around Kenyir Lake in Terengganu, Malaysia, reported sighting A. gigas. The "Kenyir monster", or "dragon fish" as the locals call it, was claimed to be responsible for the mysterious drowning of two men on 17 June. In August 2018, India Times reported that arapaima has been spotted in the Chalakudy River, following floods in Kerala; their presence in India is attributed to illegal importation for fish farming. The arapaima is depicted on both the flag and the seal of the Department of Ucayali, Peru.
== Pharmacology == Semax is a heptapeptide and synthetic analogue of a fragment of adrenocorticotropic hormone (ACTH), ACTH (4-10), of the following amino acid sequence: Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP in single-letter form). In animals, Semax rapidly elevates the levels and expression of brain-derived neurotrophic factor (BDNF) and its signaling receptor tropomyosin receptor kinase B (TrkB) in the hippocampus, and rapidly activates serotonergic and dopaminergic brain systems. Accordingly, it has been found to produce antidepressant-like and anxiolytic-like effects, attenuate the behavioral effects of exposure to chronic stress, and potentiate the locomotor activity produced by D-amphetamine. As such, it has been suggested that Semax may be effective in the treatment of depression. Though the exact mechanism of action of Semax is unclear, there is evidence that it may act through melanocortin receptors. Specifically, there is a report of Semax competitively antagonizing the action of α-melanocyte-stimulating hormone (α-MSH) at the MC4 and MC5 receptors in both in vitro and in vivo experimental conditions, indicating that it may act as an antagonist or partial agonist of these receptors. (&alpha-MSH acts as a full agonist of all five melanocortin receptors). Semax did not antagonize α-MSH at the MC3 receptor, though this receptor could still be a target of the drug. As for the MC1 and MC2 receptors, they were not assayed.
genomic imprinting An epigenetic phenomenon that causes genes to be expressed in a manner dependent upon the particular parent from which the gene was inherited. It occurs when epigenetic marks such as DNA or histone methylation are established or "imprinted" in the germ cells of a parent organism and subsequently maintained through cell divisions in the somatic cells of the organism's progeny; as a result, a gene in the progeny that was inherited from the father may be expressed differently than another copy of the same gene that was inherited from the mother.
The Orphan Drug Act of 1983 is a law passed in the United States to facilitate development of orphan drugs—drugs for rare diseases such as Huntington's disease, myoclonus, ALS, Tourette syndrome or muscular dystrophy which affect small numbers of individuals residing in the United States. Orphan drug designation does not indicate that the therapeutic is either safe and effective or legal to manufacture and market in the United States. That process is handled through other offices in the US Food and Drug Administration. Instead, the designation means only that the sponsor qualifies for certain benefits from the federal government, such as market exclusivity and reduced taxes. In 1982 an informal coalition of supporters and families of patients with rare diseases who formed National Organization for Rare Disorders (NORD) and others, called for change to legislation to support development of orphan drugs, or drugs for treating rare diseases. They succeeded in getting the United States Congress to pass the Orphan Drug Act (ODA) in early 1983. Only thirty-eight orphan drugs had been approved prior to the 1983 Act; by 2014 "468 indication designations covering 373 drugs have been approved." Partly as a result of the 1983 US Orphan Drug Act, Japan adopted it in 1993 as did the European Union in 2000.
Sources: en.wikipedia.org
== Quality, efficiency, and access == Evidence-based medicine, prevention of medical error (and other "iatrogenesis"), and avoidance of unnecessary health care are a priority in modern medical systems. These topics generate significant political and public policy attention, particularly in the United States where healthcare is regarded as excessively costly but population health metrics lag similar nations. Health spending varies by country, which results in differences in access to care and access to medicines. Health care rationing varies by country. Most developed countries provide health care to all citizens, with a few exceptions such as the United States where restrictions on health insurance coverage may limit affordability.
== Uses == Controlled clinical trials of mepiprazole in patients with irritable bowel syndrome (IBS) were also carried out and suggested some benefits of the drug in relieving symptoms of IBS in some patients. Similarly to other phenylpiperazines like trazodone, nefazodone, and etoperidone, mepiprazole produces mCPP as an active metabolite.
== Research == Deudimethyltryptamine is under development by Helus Pharma (formerly Cybin). It is under development for the treatment of generalized anxiety disorder, anxiety disorders, and depressive disorders. As of July 2026, deudimethyltryptamine is in phase 2 clinical trials for generalized anxiety disorder and phase 1 trials for anxiety disorders and depressive disorders. It was also under development for the treatment of substance-related disorders and other psychiatric disorders, but development for these indications was discontinued.
Former police officer Derek Chauvin is sentenced to 22.5 years in prison for the murder of George Floyd in Minneapolis in May 2020. June 26 COVID-19 pandemic – Michigan reports its first case of Lineage B.1.617 Delta variant in a fully vaccinated Ottawa County resident. In Southeast Michigan, a rainband sets up across Washtenaw County and Wayne County. The local weather radar estimated that some areas in Detroit received 6 in (150 mm) of rain. Local highways like I-75, I-94, and I-96 were flooded, and hundreds of cars were left stranded. 2021 Albuquerque hot air balloon crash – Five people are killed when a hot air balloon crashes into power lines in Albuquerque, New Mexico. June 26–29 – Portland, Oregon experiences a 3-day heat wave, which kills 93 people. June 29 Recreational cannabis becomes legal in New Mexico. San Jose becomes the first city in the nation to mandate that gun owners both purchase liability insurance for their firearms and to pay an annual fee to cover costs to the city's services for gun-related injuries and deaths, after the city council unanimously adopted the measures. June 30 Disgraced entertainer Bill Cosby is prematurely released from prison when the Pennsylvania Supreme Court overturns his sexual assault convictions and sentences on the grounds that his due process rights were violated. In addition to this, the highest judiciary within the Commonwealth of Pennsylvania bars any future prosecution for these crimes. A grand jury in Manhattan indicts the Trump organization, as well as CFO Allen Weisselberg.
== Further reading == Snyder, Lloyd R.; Kirkland, Joseph J.; Dolan, John W. (2009). Introduction to Modern Liquid Chromatography. doi:10.1002/9780470508183. ISBN 978-0-470-16754-0. Dong, Michael W. (2006). Modern HPLC for Practicing Scientists. doi:10.1002/0471973106. ISBN 978-0-471-72789-7. Snyder, Lloyd R.; Kirkland, Joseph J.; Glajch, Joseph L. (1997). Practical HPLC Method Development. doi:10.1002/9781118592014. ISBN 978-0-471-00703-6. Ahuja, Satinder; Rasmussen, Henrik (2007). HPLC Method Development for Pharmaceuticals. Elsevier Science. ISBN 978-0-12-370540-2. Ahuja, Satinder; Dong, M. W. (2005). Handbook of pharmaceutical analysis by HPLC (1st ed.). Amsterdam Boston: Elsevier Academic Press. ISBN 978-0-12-088547-3. Kazakevich, Yuri; Lobrutto, Rosario, eds. (2007). HPLC for Pharmaceutical Scientists. doi:10.1002/0470087951. ISBN 978-0-471-68162-5. Neue, Uwe D. (1997). HPLC columns: theory, technology, and practice. New York, NY: Wiley VCH. ISBN 978-0-471-19037-0. McMaster, Marvin C. (2007). HPLC. doi:10.1002/0470079096. ISBN 978-0-471-75401-5.
Sources: en.wikipedia.org
=== Evaluating similarity === Often the purpose of seeking a structural superposition is not so much the superposition itself, but an evaluation of the similarity of two structures or a confidence in a remote alignment. A subtle but important distinction from maximal structural superposition is the conversion of an alignment to a meaningful similarity score. Most methods output some sort of "score" indicating the quality of the superposition. However, what one actually wants is not merely an estimated "Z-score" or an estimated E-value of seeing the observed superposition by chance but instead one desires that the estimated E-value is tightly correlated to the true E-value. Critically, even if a method's estimated E-value is precisely correct on average, if it lacks a low standard deviation on its estimated value generation process, then the rank ordering of the relative similarities of a query protein to a comparison set will rarely agree with the "true" ordering. Different methods will superimpose different numbers of residues because they use different quality assurances and different definitions of "overlap"; some only include residues meeting multiple local and global superposition criteria and others are more greedy, flexible, and promiscuous. A greater number of atoms superposed can mean more similarity but it may not always produce the best E-value quantifying the unlikeliness of the superposition and thus not as useful for assessing similarity, especially in remote homologs.
The first true chromatography is usually attributed to the Russian-Italian botanist Mikhail Tsvet. Tsvet applied his observations with filter paper extraction to the new methods of column fractionation that had been developed in the 1890s for separating the components of petroleum. He used a liquid-adsorption column containing calcium carbonate to separate yellow, orange, and green plant pigments (what are known today as xanthophylls, carotenes, and chlorophylls, respectively). The method was described on December 30, 1901, at the 11th Congress of Naturalists and Doctors (XI съезд естествоиспытателей и врачей) in Saint Petersburg. The first printed description was in 1903, in the Proceedings of the Warsaw Society of Naturalists, section of biology. He first used the term chromatography in print in 1906 in his two papers about chlorophyll in the German botanical journal, Berichte der Deutschen Botanischen Gesellschaft. In 1907 he demonstrated his chromatograph for the German Botanical Society. Mikhail's surname "Цвет" means "color" in Russian, so there is the possibility that his naming the procedure chromatography (literally "color writing") was a way that he could make sure that he, a commoner in Tsarist Russia, could be immortalized. In a 1903 lecture (published in 1905), Tsvet also described using filter paper to approximate the properties of living plant fibers in his experiments on plant pigments—a precursor to paper chromatography.
As such, EMP therapy results in considerably stronger androgen deprivation than orchiectomy. Metabolites of EMP, including estramustine, estromustine, estradiol, and estrone, have been found to act as weak antagonists of the androgen receptor (EC50Tooltip half-maximal effective concentration = 0.5–3.1 μM), although the clinical significance of this is unknown. Extremely high levels of estradiol and estrone occur during EMP therapy. The estrogenic metabolites of EMP are responsible for its most common adverse effects and its cardiovascular toxicity. EMP has been described as having relatively weak estrogenic effects in some publications. However, it has shown essentially the same rates and degrees of estrogenic effects, such as breast tenderness, gynecomastia, cardiovascular toxicity, changes in liver protein synthesis, and testosterone suppression, as high-dose diethylstilbestrol and ethinylestradiol in clinical studies. The notion that EMP has relatively weak estrogen activity may have been based on animal research, which found that EMP had 100-fold lower uterotrophic effects than estradiol in rats, and may also not have taken into account the very high doses of EMP used clinically in humans. The mechanism of action of the cytostatic effects of EMP is complex and only partially understood. EMP is considered to mainly be a mitotic inhibitor, inhibiting mechanisms involved in the mitosis phase of the cell cycle.
=== Prevalence of use === The use of herbal remedies is more prevalent in people with chronic diseases, such as cancer, diabetes, asthma, and end-stage kidney disease. Multiple factors such as gender, age, ethnicity, education and social class are also shown to have associations with the prevalence of herbal remedy use.
ATP is the phosphorylated version of adenosine diphosphate (ADP), which stores energy in a cell and powers most cellular activities. ATP is the energized form, while ADP is the (partially) depleted form. NADP+ is an electron carrier which ferries high energy electrons. In the light reactions, it gets reduced, meaning it picks up electrons, becoming NADPH.
Sources: en.wikipedia.org
Refrigeration between 2 and 8 degrees Celsius with protection from light is the common recommendation. Many laboratories choose frozen storage at minus 20 degrees Celsius when the material will not be used soon. Repeated temperature cycling is generally avoided.
Mass spectrometry gives the observed mass, which is compared against the value calculated from the sequence. Peptide mapping after digestion provides a second, sequence-level check. Chromatographic retention alone is not sufficient for identity.
Antibodies raised against one GHRH-related peptide may bind other members of the same family. That cross-reactivity inflates or distorts measured concentrations. Assay validation with defined standards is therefore necessary before results are interpreted.
多肽在反相柱上按疏水性差异分离，能有效区分主峰、缺失序列片段与氧化产物。配合紫外检测可获得可量化的纯度百分比，是肽类分析的常规手段。